

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

**STA fluocinolone acetonide ocular implant for treating
recurrent non-infectious uveitis**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Consultation

- | |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
|---|

No equality issues were identified during the scoping process.
--

- | |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
|--|

It was raised that the long-lasting design of the fluocinolone acetonide implant could improve adherence to treatment for some people e.g. people with dementia or mental health problems. No preliminary recommendations have been made, but the committee will be mindful of this as a potential equality consideration when it makes its decision at the second appraisal committee meeting.

- | |
|--|
| 3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these? |
|--|

The committee noted that the fluocinolone acetonide implant may be of particular benefit to women who want to start a family or who are pregnant, because systemic treatments would not be suitable for these women. No preliminary recommendations have been made, but the committee will be

mindful of this as a potential equality consideration when it makes its decision at the second appraisal committee meeting.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

N/A – the committee was minded not to recommend fluocinolone.

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

N/A

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

N/A

7. Have the committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?

Yes, see section 3.19.

Approved by Associate Director (name): Jasdeep Hayre

Date: 20/03/2019

Final appraisal determination

(when an ACD issued)

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these?

A stakeholder highlighted that that women may benefit more from the fluocinolone acetonide implant because high doses of systemic steroids may adversely affect women's bone density more than men's. Because the committee's recommendation is for the whole population covered by the marketing authorisation, the committee concluded that its recommendations do not have a different effect on people protected by the equality legislation than on the wider population.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No.

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

N/A

5. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

Yes, section 3.19.

Approved by Associate Director (name): Frances Sutcliffe.....

Date: 03/06/2019